Pharma Regulatory Affairs in Mexico
Upcoming SlideShare
Loading in...5
×
 

Pharma Regulatory Affairs in Mexico

on

  • 6,175 views

 

Statistics

Views

Total Views
6,175
Views on SlideShare
3,319
Embed Views
2,856

Actions

Likes
1
Downloads
131
Comments
1

7 Embeds 2,856

http://latampharmara.com 2804
http://niniguaia.wordpress.com 36
http://www.linkedin.com 10
http://www.google.com.mx 2
https://www.linkedin.com 2
http://translate.googleusercontent.com 1
http://www.google.com.ar 1
More...

Accessibility

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
  • Hi Maria

    great slide deck!

    Do you have any information regarding:

    third party evaluation process

    agreement for innovation?



    Thank you for your assistance.

    Regards

    Kirti
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment
  • The service sector employs around 70% of the active population and includes transportation, commerce, warehousing, restaurant and hotels, arts and entertainment, health, education, financial and banking services, telecommunications as well as public administration and defense. Mexico's service sector is strong, and hasreplaced Brazil's as the largest service sector in Latin America in value.Industry is a growing sector, the main areas are Aircraft, automobile industry, petrochemicals, cement and construction, textiles, food and beverages, mining, consumer durables and tourism. It has benefited from trade liberalization.
  • The service sector employs around 70% of the active population and includes transportation, commerce, warehousing, restaurant and hotels, arts and entertainment, health, education, financial and banking services, telecommunications as well as public administration and defense. Mexico's service sector is strong, and hasreplaced Brazil's as the largest service sector in Latin America in value.Industry is a growing sector, the main areas are Aircraft, automobile industry, petrochemicals, cement and construction, textiles, food and beverages, mining, consumer durables and tourism. It has benefited from trade liberalization.
  • The service sector employs around 70% of the active population and includes transportation, commerce, warehousing, restaurant and hotels, arts and entertainment, health, education, financial and banking services, telecommunications as well as public administration and defense. Mexico's service sector is strong, and hasreplaced Brazil's as the largest service sector in Latin America in value.Industry is a growing sector, the main areas are Aircraft, automobile industry, petrochemicals, cement and construction, textiles, food and beverages, mining, consumer durables and tourism. It has benefited from trade liberalization.
  • The service sector employs around 70% of the active population and includes transportation, commerce, warehousing, restaurant and hotels, arts and entertainment, health, education, financial and banking services, telecommunications as well as public administration and defense. Mexico's service sector is strong, and hasreplaced Brazil's as the largest service sector in Latin America in value.Industry is a growing sector, the main areas are Aircraft, automobile industry, petrochemicals, cement and construction, textiles, food and beverages, mining, consumer durables and tourism. It has benefited from trade liberalization.
  • The service sector employs around 70% of the active population and includes transportation, commerce, warehousing, restaurant and hotels, arts and entertainment, health, education, financial and banking services, telecommunications as well as public administration and defense. Mexico's service sector is strong, and hasreplaced Brazil's as the largest service sector in Latin America in value.Industry is a growing sector, the main areas are Aircraft, automobile industry, petrochemicals, cement and construction, textiles, food and beverages, mining, consumer durables and tourism. It has benefited from trade liberalization.
  • The service sector employs around 70% of the active population and includes transportation, commerce, warehousing, restaurant and hotels, arts and entertainment, health, education, financial and banking services, telecommunications as well as public administration and defense. Mexico's service sector is strong, and hasreplaced Brazil's as the largest service sector in Latin America in value.Industry is a growing sector, the main areas are Aircraft, automobile industry, petrochemicals, cement and construction, textiles, food and beverages, mining, consumer durables and tourism. It has benefited from trade liberalization.
  • The increase in public expenditure in healthcare is directly reflected in the expenditure in medicines, which grew 86% between 2005 and 2011.
  • Mexico is the second country of the Organization for Economic Cooperation and Development in expenditure in medicines as a percentage of the total expenditure in healthcare. The expenditure in medicines as a percentage of the GDP is also above the OECD average.
  • During the period 2005-2011, the out-of-pocket health expenditure decreased by 9%, at an average annual rate of -1.5, as a result of the effort of the federal government to implement policies of universal healthcare, such as incentives to import, production and commercialization of generic drugs.
  • InLatAm: after BrazilWorldwide: after USA, Japan, Germany, China, France, Canada, Brazil, Italy, Spain and the UK
  • InLatAm: after BrazilWorldwide: after USA, Japan, Germany, China, France, Canada, Brazil, Italy, Spain and the UK
  • The service sector employs around 70% of the active population and includes transportation, commerce, warehousing, restaurant and hotels, arts and entertainment, health, education, financial and banking services, telecommunications as well as public administration and defense. Mexico's service sector is strong, and hasreplaced Brazil's as the largest service sector in Latin America in value.Industry is a growing sector, the main areas are Aircraft, automobile industry, petrochemicals, cement and construction, textiles, food and beverages, mining, consumer durables and tourism. It has benefited from trade liberalization.
  • In Mexico the drug registration procedure will depend on the type of product that it is intended to get registered.After document submission, the official timeline for an answer is 6 months. Until last year, the norm was between 1 and 2 years. Last, year, a new option was introduced which contemplates the possibility of having third parties (consultants) previously evaluated and approved by COFEPRIS, do a pre-evaluation of the dossiers, which expedites the posterior revision by COFEPRIS, and at the same times lightens the burden for the evaluators at the health authority, allowing a quickest revision of all submissions.
  • Before submission for registration, all quality, efficacy and security information has to be reviewed by the New Molecule Committee.Submission package consists of:FormStability studiesEfficacy and safety information (publications, studies)Labeling textsPatent or licensing documentsOrigin identification and GMP certificate for DS+DPTechnical information for raw materials:Monograph, control methods, validation, bibliographic referencesCertificates of analysis, spectra, chromatogramsTechnical information for finished product:Monograph, control methods, validation, bibliographic referencesCertificates of analysis, spectra, chromatogramsCopy of manufacturing orders of batches used for stability testsTechnical information for packaging materials:Description and capacity of primary and secondary packaging materialsFor primary packaging: tightness test, results and bibliographic referenceCopy of packaging orders of batches used for stability testsIf the drug product will be manufactured in a country different than Mexico, these additional documents must be included:CPP of originDS+DP GMP certification of origin by a recognized country (apostilled/legalized)Authenticated representation letter, if solicitor is not affiliate or headquarter of manufacturing company
  • Before submission for registration, all quality, efficacy and security information has to be reviewed by the New Molecule Committee.Submission package consists of:FormStability studiesEfficacy and safety information (publications, studies)Labeling textsPatent or licensing documentsOrigin identification and GMP certificate for DS+DPTechnical information for raw materials:Monograph, control methods, validation, bibliographic referencesCertificates of analysis, spectra, chromatogramsTechnical information for finished product:Monograph, control methods, validation, bibliographic referencesCertificates of analysis, spectra, chromatogramsCopy of manufacturing orders of batches used for stability testsTechnical information for packaging materials:Description and capacity of primary and secondary packaging materialsFor primary packaging: tightness test, results and bibliographic referenceCopy of packaging orders of batches used for stability testsIf the drug product will be manufactured in a country different than Mexico, these additional documents must be included:CPP of originDS+DP GMP certification of origin by a recognized country (apostilled/legalized)Authenticated representation letter, if solicitor is not affiliate or headquarter of manufacturing company
  • Before submission for registration, all quality, efficacy and security information has to be reviewed by the New Molecule Committee.Submission package consists of:FormStability studiesEfficacy and safety information (publications, studies)Labeling textsPatent or licensing documentsOrigin identification and GMP certificate for DS+DPTechnical information for raw materials:Monograph, control methods, validation, bibliographic referencesCertificates of analysis, spectra, chromatogramsTechnical information for finished product:Monograph, control methods, validation, bibliographic referencesCertificates of analysis, spectra, chromatogramsCopy of manufacturing orders of batches used for stability testsTechnical information for packaging materials:Description and capacity of primary and secondary packaging materialsFor primary packaging: tightness test, results and bibliographic referenceCopy of packaging orders of batches used for stability testsIf the drug product will be manufactured in a country different than Mexico, these additional documents must be included:CPP of originDS+DP GMP certification of origin by a recognized country (apostilled/legalized)Authenticated representation letter, if solicitor is not affiliate or headquarter of manufacturing company
  • Before submission for registration, all quality, efficacy and security information has to be reviewed by the New Molecule Committee.Submission package consists of:FormStability studiesEfficacy and safety information (publications, studies)Labeling textsPatent or licensing documentsOrigin identification and GMP certificate for DS+DPTechnical information for raw materials:Monograph, control methods, validation, bibliographic referencesCertificates of analysis, spectra, chromatogramsTechnical information for finished product:Monograph, control methods, validation, bibliographic referencesCertificates of analysis, spectra, chromatogramsCopy of manufacturing orders of batches used for stability testsTechnical information for packaging materials:Description and capacity of primary and secondary packaging materialsFor primary packaging: tightness test, results and bibliographic referenceCopy of packaging orders of batches used for stability testsIf the drug product will be manufactured in a country different than Mexico, these additional documents must be included:CPP of originDS+DP GMP certification of origin by a recognized country (apostilled/legalized)Authenticated representation letter, if solicitor is not affiliate or headquarter of manufacturing company
  • Before submission for registration, all quality, efficacy and security information has to be reviewed by the New Molecule Committee.Submission package consists of:FormStability studiesEfficacy and safety information (publications, studies)Labeling textsPatent or licensing documentsOrigin identification and GMP certificate for DS+DPTechnical information for raw materials:Monograph, control methods, validation, bibliographic referencesCertificates of analysis, spectra, chromatogramsTechnical information for finished product:Monograph, control methods, validation, bibliographic referencesCertificates of analysis, spectra, chromatogramsCopy of manufacturing orders of batches used for stability testsTechnical information for packaging materials:Description and capacity of primary and secondary packaging materialsFor primary packaging: tightness test, results and bibliographic referenceCopy of packaging orders of batches used for stability testsIf the drug product will be manufactured in a country different than Mexico, these additional documents must be included:CPP of originDS+DP GMP certification of origin by a recognized country (apostilled/legalized)Authenticated representation letter, if solicitor is not affiliate or headquarter of manufacturing company
  • Before submission for registration, all quality, efficacy and security information has to be reviewed by the New Molecule Committee.Submission package consists of:FormStability studiesEfficacy and safety information (publications, studies)Labeling textsPatent or licensing documentsOrigin identification and GMP certificate for DS+DPTechnical information for raw materials:Monograph, control methods, validation, bibliographic referencesCertificates of analysis, spectra, chromatogramsTechnical information for finished product:Monograph, control methods, validation, bibliographic referencesCertificates of analysis, spectra, chromatogramsCopy of manufacturing orders of batches used for stability testsTechnical information for packaging materials:Description and capacity of primary and secondary packaging materialsFor primary packaging: tightness test, results and bibliographic referenceCopy of packaging orders of batches used for stability testsIf the drug product will be manufactured in a country different than Mexico, these additional documents must be included:CPP of originDS+DP GMP certification of origin by a recognized country (apostilled/legalized)Authenticated representation letter, if solicitor is not affiliate or headquarter of manufacturing company
  • Before submission for registration, all quality, efficacy and security information has to be reviewed by the New Molecule Committee.Submission package consists of:FormStability studiesEfficacy and safety information (publications, studies)Labeling textsPatent or licensing documentsOrigin identification and GMP certificate for DS+DPTechnical information for raw materials:Monograph, control methods, validation, bibliographic referencesCertificates of analysis, spectra, chromatogramsTechnical information for finished product:Monograph, control methods, validation, bibliographic referencesCertificates of analysis, spectra, chromatogramsCopy of manufacturing orders of batches used for stability testsTechnical information for packaging materials:Description and capacity of primary and secondary packaging materialsFor primary packaging: tightness test, results and bibliographic referenceCopy of packaging orders of batches used for stability testsIf the drug product will be manufactured in a country different than Mexico, these additional documents must be included:CPP of originDS+DP GMP certification of origin by a recognized country (apostilled/legalized)Authenticated representation letter, if solicitor is not affiliate or headquarter of manufacturing company
  • Pesticides, products used in agriculture and drugsSimilar biotherapeutic product
  • In Mexico the drug registration procedure will depend on the type of product that it is intended to get registered.After document submission, the official timeline for an answer is 6 months. Until last year, the norm was between 1 and 2 years. Last, year, a new option was introduced which contemplates the possibility of having third parties (consultants) previously evaluated and approved by COFEPRIS, do a pre-evaluation of the dossiers, which expedites the posterior revision by COFEPRIS, and at the same times lightens the burden for the evaluators at the health authority, allowing a quickest revision of all submissions.
  • In Mexico the drug registration procedure will depend on the type of product that it is intended to get registered.After document submission, the official timeline for an answer is 6 months. Until last year, the norm was between 1 and 2 years. Last, year, a new option was introduced which contemplates the possibility of having third parties (consultants) previously evaluated and approved by COFEPRIS, do a pre-evaluation of the dossiers, which expedites the posterior revision by COFEPRIS, and at the same times lightens the burden for the evaluators at the health authority, allowing a quickest revision of all submissions.
  • Reports for the last two years: manufactured batches, rejected batches, released batches investigated, reprocessed batches, complaints, refunds, market recalls.
  • Slow and fastacetlylators, depending on the metabolic route the drug can be eliminated faster or more slowly.
  • Revision times for innovative drug products

Pharma Regulatory Affairs in Mexico Pharma Regulatory Affairs in Mexico Presentation Transcript

  • Pharma Regulatory Affairs in Mexico Maria Ines Guaia - Informa Conference: Regulatory Affairs in Emerging Markets - Prague, October 2013
  • Disclaimer • For educational purposes, some tables and graphs have been borrowed from an informative COFEPRIS presentation. You can find the complete original presentation in the following link: http://www.deloitte.com/assets/DcomMexico/Local%20Assets/Documents/mx(esmx)PanoramaMexico_IndustriaCofepris.pdf
  • Mexico: an emerging economy $1.177 trillion GDP Services 70% #14 World #2 Latin America Industry 26% Annual growth rate: 3.9 (2012) 3.5 (exp. 2013) Agriculture 4% 120 million people (est. 2012) 46% below poverty line
  • Mexican GDP growth Source: COFEPRIS
  • Mexican GDP growth relative to US GDP growth Source: COFEPRIS
  • Mexican balance of payments Accounting record of all monetary transactions between a country and the rest of the world. Indicator of a country's position in the global economy. Source: COFEPRIS / Data: 2010
  • Mexican fiscal deficit Difference between public expenditure and income. Indicator of a government’s budget and dependence on credit. Source: COFEPRIS / Data: 2011
  • Direct foreign investment in Mexico Source: COFEPRIS
  • Public expenditure in drug products Source: COFEPRIS
  • Public expenditure in drug products - global comparison Source: COFEPRIS
  • Out-of-pocket health expenditure as a percentage of total health expenditure Source: COFEPRIS
  • The pharma industry in Mexico % of GDP 1.2 % of manufacturing GDP 6.9 Annual exports (millions of USD) 2,200 Total pharma market (billions of dollars) 13 Direct employment 78,500 Indirect employment 330,000 2nd biggest in LatAm 11th biggest worldwide Source: COFEPRIS Steady annual growthrate 2005-2011: average of 4.8%
  • The pharma industry in Mexico Mainly internal consumption (exports only 14% of production) Source: COFEPRIS
  • COFEPRIS: the Mexican Health Authority Regulates: • Food and beverages • Tobacco products • Healthcare supplies (including drugs, medical devices, vaccines, blood and tissues, etc.) • Healthcare services • Other consumer goods (cosmetics) • Pesticides, plant nutrients and toxic substances • Emergencies • Occupational health • Environmental risks 92 billion $ market! (around 10% of GDP) Through all the supply chain • Production • Distribution • Commercialization • Imports • Exports • Advertisement • Sales and supply
  • COFEPRIS: the Mexican Health Authority July 2012: COFEPRIS recognized as Health Authority of Regional Reference COFEPRIS Commisionate: Mikel Arriola Photo: PAHO Other ARRs: ANVISA (Brazil), ANMAT (Argentina), INVIMA (Colombia), CECMED (Cuba)
  • Drug product Registration in Mexico General overview
  • Drug registration in Mexico Timeline to approval Registration period: 5 years officially: 6 months In reality: very variable and changing 12 – 24 months Submission for registration renewal: at least 6 months before registration expiry new entity Small molecules Registration cases Biotechs generic new entity biocomparable Vaccines Orphan drugs Before submission: Committee of New Molecules
  • Dossier structure for the different registration cases Vaccines New Molecules • • • • Module I. Legal/Administrative information Module II. Quality information Module III. Preclinical studies Module IV. Clinical studies • • • • Orphan drugs Generic drugs • • • Module I. Legal/Administrative information Module II. Quality information Module III. Bioavailability and/or bioequivalence Module I. Legal/Administrative information Module II. Quality information Module III. Preclinical studies Module IV. Clinical studies • • • • • Module I. Legal/Administrative information Module II. Quality information Module III. Justification of ‘orphan drug’ status Module IV. Preclinical studies Module V. Clinical studies
  • Dossier structure content of the modules Module I. Legal/Administrative information 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. Form. Proof of payment of fee. Sanitary authorization. (licencia sanitaria) For foreign manufacturing site provide licence, certificate or other document authorizing the site to manufacture the pharmaceutical products of interest, issued by country of origin, legalized or apostilled, translated to Spanish by an official translator (perito traductor). ‘Responsible sanitario’ notice. Labeling texts (if applicable). Complete and summarized prescription information. GMP certificate for manufacturing site of API. GMP certificate for manufacturing site of finished product. GMP certificate for manufacturing site of diluent (if applicable). For drug products manufactured outside of Mexico: Certificate of Pharmaceutical Product (CPP) of origin, apostilled or legalized, with official translation (perito traductor). Representation letter, assigning the legal representative of the foreign company in Mexico. (Reccomended: broad power of representation letter, minimum validity time of 5 years. Commercial name. Intellectual property information. Information on the waiver for the local manufacturing facility requirement.
  • Dossier structure content of the modules Module II. Quality information 1. API 1.1. Manufacturing information 1.2. General information 1.3. Quality control 1.3.1. Literature/Pharmacopoeial references. Specifications. Analytical methods. Validation reports. Certificates of analysis (CoAs). 2. Excipients and additives 2.1. For new additives, usage safety information 2.2. Quality control 2.2.1. Literature/Pharmacopoeial references. Specifications. Analytical methods. Validation reports. Certificates of analysis (CoAs).
  • Dossier structure content of the modules Module II. Quality information (cont.) 3. Finished product 3.1. Pharmaceutical development 3.2. Formula 3.3. Manufacturing information 3.3.1. Manufacturing/packaging order, in-process controls. 3.4. Quality control 3.4.1. Monograph 3.4.2. Specifications 3.4.3. Analytical methods and validation reports (if applicable) 3.4.4 Certificates of analysis (CoAs). 3.5 Stability 3.5.1 Stability protocol 3.5.2. Tabulated stability data 3.5.3 Analytical evidence for first and final testing points. 3.5.4 Conclusions
  • Dossier structure content of the modules Module II. Quality information (cont.) 4. Packaging materials 4.1. Description and capacity of primary packaging materials. 4.2. Description and capacity of secondary packaging materials. 4.3. Description, capacity and information of any additional materials or devices.
  • Dossier structure content of the modules Module III. Preclinical studies (for new molecules, vaccines, orphan drugs). 1. Preclinical studies 1.1. Pharmacodynamics' studies 1.2. Pharmacokinetic studies 1.3. Toxicology Module IV. Clinical studies (for new molecules, vaccines, orphan drugs). 1. Clinical studies 1.1. Phase I studies 1.2. Phase II studies 1.3. Phase III studies 1.4. Phase IV studies (if applicable) 1.5. For combination of two or more drugs: risk-benefit assessment.
  • Dossier structure content of the modules Module III. Bioavailability and/or bioequivalence (for generic drug products) 1. Type of test 1.1. A 1.2. A (3) 1.3. B 1.4. C
  • Biotech regulations: Mexico at the vanguard Late ‘90s 1997 1998 Some legal adaptations to include innovative biotech drug products Modification of General Health Law – all biotech products Inclusion of some concepts and guidelines in Health Supplies Regulation 2004 2005 USA – EU EU: First specific started guidelines discussions on regulations for SBP +170 biotech drug products approved 2007 2009 Starts congress discussion in Mexico Modification to Health General Law – general principles for SBP Development of specific, detailed regulation COFEPRIS, industry, other actors Oct 2011 – April 2012 Modification of General Health Law Sep 2012 Operative guidelines became effective
  • Drug registration in Mexico foreign manufacturers Until August 2008: local manufacturing site requirement the solicitor of a registration had to own a manufacturing facility in Mexico Foreign manufacturer • • License to manufacture medical products GMP certificate Currently: Solicitor must hold license, permit or similar document issued by the country of origin authorizing the manufacturing of medical products Legal representative Warehouse (storage and distribution) Importer (Mexican company) Lab of Analysis (Authorized Third Parties) Unit of pharmacovigilanc e Sanitary responsible
  • New Molecule Committee For registration of novel compounds
  • Presentation at the New Molecule Committee Cases in which a drug is considered a “New Molecule” • New drug substances (new in the world or new for Mexico) • New combinations of drug substances (for Mexico) • New indications • Other special cases (e.g. similar biotherapeutic products) 1- Request meeting with the New Molecule Committe. (before dossier submission) 2- Presentation by company on the product, followed by questions by the members of the committee. 3- After the meeting, the committee will issue a report thet will be attached to the dossier for submission.
  • Pre-revision of submission dossiers by Authorized Third Parties A solution for eternal approval timelines
  • Pre-revision of dossier Starting in 2012, the possibility of having submission dossiers pre-revised by private parties especially authorized by COFEPRIS was introduced. How does it work? After all the necessary meetings and exchange of information, the ATP will issue a technical report. If this final report is positive, it can be attached to the submission package for registration. This submission package will enter the COFEPRIS through a special fast-track channel and will be revised in a much shorter time than applications going through the conventional channel. This option is available for new drug applications, renewal of registration certificate and variations. COFEPRIS doesn’t have any inference in the relations and terms of agreement between clients and ATP. Main benefits of this new option • Cut current revision times. • Avoid unnecessary deficiency letters. The technical report that the ATP issues does not replace the evaluation and decision by COFEPRIS.
  • Significant reduction in processing times! NEW August 2013: expansion of the Third Authorized Parties’ pre-revision scheme to include biotech products Source: COFEPRIS
  • GMP verification and certification
  • GMP verification by COFEPRIS GMP Certificates issued by FDA When? • For new registration and manufacturing changes of biologic, biotech and hemoderivate products. • For new registration or renewal of drug products or drug substances of any kind manufactured in countries not considered as high sanitary surveillance by COFEPRIS. Inspection is required prior to submission the certificate is an important document to be annexed to the submission dossier What? Manufacturing sites of drug substance and drug product – DP/DS specific (USA), ANVISA (Brazil), Health Canada (Canada), EMA (EU), Pharmaceutical and Food Safety Bureau (Japan), and Therapeutic Goods Administration (Australia) are accepted. Cooperation within the Pacific Alliance bloc and with other Sanitary Authorities of Regional Reference Request for inspection • Submit form and required documents • Propose two inspection dates (production of DS/DP) and inspection schedule • Propose hotel and flight options. Cost of visit + travel expenses: company • Arrange a Spanish translator • Timeline to get an inspection: about 3 months
  • Required info and documents • Name and general data of the applying company, authorization • Name of DP/DS – use, action, indication • Name and address of all sites involved in manufacturing process, description of process stages • Manufacturing process – list and description of other DS/DP manufactured in same line • Person designated by the applicant to be in charge • Technical documents:  Organization charts  Architectural drawings  Flowchart of manufacturing process  General summary of quality system  Validation master plan  Two last annual product reports Payment • All documents in Spanish, or English with Spanish translation, verified and signed by technical responsible Documents issued by foreign authorities: apostilled or legalized and translated by certified translator NEW! AUGUST 2013: Open call to private parties to enroll as inspectors for DS and DP facilities (Authorized Third Parties)
  • Clinical trials in Mexican population
  • Local Clinical Trials in Mexico • Why? Pharmacogenomic studies have shown that drug metabolism in Mexican-Hispanic population can be influenced by its genetic makeup. • In which cases? Local clinical studies are required by COFEPRIS for: • New molecules • Biotech and biocomparable products • Generic drugs that are not commercialized anywhere else in the world. • Other cases upon authority request • When? • Previous submission and approval of clinical protocol – Have results before submission for registration. • How? When clinical studies are multicentric, Mexican population must be included. Sample size: not specified in regulations; to be calculated based on incidence of disease. If Mexican patients are not included in the clinical trials: New Molecule Committee will request pharmacokinetic studies to evidence not significant differences in safety or efficacy in Mexicans. • Good Clinical Practices guidelines
  • Agreement for innovation October 2012
  • Agreement for Innovation Three main tenants 1. Give strong support for innovation projects proposed by the national sector: expedition of approval of clinical protocols to be carried out in Mexican clinical centers, follow-up on the execution of the studies, and expedition of registration approval timelines for drug products manufactured in Mexico, from the current average of 240 working days to 60. 2. Strengthen the import of innovative drugs to the Mexican market: recognition of product registrations in the USA, Canada, Switzerland, Australia and the EU and expedition in registration approval timeline for drug products being marketed in any of these countries from a current average of 360 working days to 60. 3. Make Mexico the first country of commercialization of new innovative drug products: modification of the Regulations for Healthcare Supplies: the previously compulsory requirement of providing a CPP of origin offers now the alternative of being waived if a report of clinical trials on Mexican population is submitted.
  • Agreement for Innovation Results: reduction in dossier revision times Source: COFEPRIS
  • Agreement for Innovation Concrete results • 88 new innovative drug products have entered the Mexican market, most of them through the expedited revision process for registration of innovative imported drugs registered in high-sanitary-surveillance countries, and including five orphan drugs. Most of the newly approved drugs target cardiovascular, oncologic or cerebrovascular conditions. • Increase of 20% from 2011 to 2013 in applications for clinical trials in Mexico (current figure: 388 applications), and COFEPRIS is implementing measures to decentralize the revision of clinical protocols to the National Institutes of Health in order to reduce evaluation times, from 90 to 30 days. • In January 2013, one new drug was approved in Mexico before any other country in the world, making Mexico a worldwide pioneer for an innovative drug product for the first time: Lixisenatide (Sanofi Pasteur), trade name Lyxumia, the latest pharmaceutical innovation to treat Type 2 Diabetes, a once-daily injectable GLP-1 receptor agonist.
  • Coming soon: Regulations on personalized medicine/pharmacogenomics
  • Regulations on personalized medicine Guidelines coming soon • Guidelines to guarantee safety and effectiveness of personalized therapies based on pharmacogenomics approach • Define specific GMP requirements for pharmacogenomics-based products. • Make Mexico a pioneer in regulation for this kind of product in Latin America.
  • Thank you! Gracias! Děkuji! www.niniguaia.wordpress.com